bullish

Medikaloka Hermina - Steady FY24F Growth Outlook Remains Intact Despite Muted Inpatient Volume

121 Views31 Oct 2024 19:31
Broker
Despite weaker inpatient volume in 3Q24, we believe HEAL is on track to meet its FY24F rev. target (Rp6.6-6.7tr) and EBITDA margin (~28%).
What is covered in the Full Insight:
  • Introduction to Medikaloka Hermina's FY24F Outlook
  • Impact of Weaker Inpatient Volume on Earnings
  • Potential Margin Expansion in FY25F
  • Analysis of Operational and Financial Performance
  • Key Risks and Valuation Analysis
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 11-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
BRI Danareksa Research
External broker reports(aggregated public sources)
BRI Danareksa Research
IndonesiaEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x